Refractory Tumor Clinical Trial
Official title:
Phase IIa Dose-Expansion and Biomarker Study of OPB-111077 in An Enriched Population of Treatment-Refractory Advanced Solid Tumors
This is a phase IIa open-label, non-randomized dose-expansion study of OPB-111077 in patients with advanced, treatment refractory cancers who have biopsy-amenable lesions at study entry.
Status | Recruiting |
Enrollment | 52 |
Est. completion date | November 30, 2020 |
Est. primary completion date | May 22, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 99 Years |
Eligibility |
Inclusion Criteria: 1. Histologically confirmed, locally recurrent or metastatic solid tumors, who have failed standard treatment 2. Subjects with NPC will be eligible as long as they have received prior platinum therapy 3. Subjects with other types of solid tumors will be eligible if: i) their archival tumor sample shows over-expression oxidative phosphorylation markers e.g., PGC-1a/ SIRT1 or ii) they have oncogene-addicted cancers (e.g., EGFR mutation-positive NSCLC, EML4-ALK fusion NSCLC, BRAF-mutant melanomas, GIST, RET-driven thyroid cancers) which have become resistant to primary TKI therapy 4. All subjects must have at least one tumour lesion (primary or metastatic) that is suitable for free-hand or image-guided biopsy at baseline. 5. Age = 21 years, Eastern Cooperative Oncology Group (ECOG) performance status < 1 6. Adequate bone marrow, liver and renal function 7. Baseline serum lactate ¬<3mmol/l 8. Capable of swallowing tablets 9. Recovery from any previous drug- or procedure-related toxicity to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0 Grade 0 or 1 (except alopecia), or to baseline preceding the prior treatment. 10. Signed informed consent obtained before any study specific procedure. Subjects must be able to understand and be willing to sign the written informed consent. Exclusion Criteria: 1. Chemotherapy, radiotherapy, surgery, immunotherapy or other therapy within 3 weeks of starting investigational medicinal product (IMP). 2. Use of any prohibited medications (CYP3A4 inhibitors and inducers) or medications which may predispose to lactic acidosis (e.g., metformin, nucleoside analogue reverse within 1 week prior to start of study drug administration 3. Pregnancy or breastfeeding. 4. Women of childbearing potential not employing adequate contraception. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of study medication, and a negative result must be documented before start of study medication. Women of childbearing potential and men, must agree to use adequate contraception (barrier method of birth control) upon signing the informed consent form until at least 3 months after the last study drug administration. 5. Known or suspected allergy to the investigational agent or any agent given in association with this study. 6. Concurrent cancer which is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumours (Ta, Tis & T1) or any cancer curatively treated less than 3 years prior to study entry. 7. Interstitial lung disease with ongoing signs and symptoms at the time of screening. 8. Patients with CTCAE Grade 2 or higher peripheral neuropathy. 9. History of significant cardiac disease: congestive cardiac failure > NYHA class II, ongoing unstable angina, new-onset angina or myocardial infarction within the past 3 months |
Country | Name | City | State |
---|---|---|---|
Singapore | National University Hospital, Singapore | Singapore |
Lead Sponsor | Collaborator |
---|---|
National University Hospital, Singapore | Otsuka Pharmaceutical Co., Ltd. |
Singapore,
Alam MM, Lal S, FitzGerald KE, Zhang L. A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors. Clin Transl Med. 2016 Mar;5(1):3. doi: 10.1186/s40169-016-0082-9. Epub 2016 Jan 26. — View Citation
Vellinga TT, Borovski T, de Boer VC, Fatrai S, van Schelven S, Trumpi K, Verheem A, Snoeren N, Emmink BL, Koster J, Rinkes IH, Kranenburg O. SIRT1/PGC1a-Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer. Clin Cancer Res. 2015 Jun 15;21(12):2870-9. doi: 10.1158/1078-0432.CCR-14-2290. Epub 2015 Mar 16. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response rates | This will be calculated as the percentage of evaluable patients achieving complete and partial response with OPB-111077 treatment, according to the RECIST 1.1 criteria | 3 years | |
Secondary | Metabolic response rates | This will be calculated as the percentage of evaluable patients achieving complete and partial metabolic response on 18F]-FDG PET/CT after 2 cycles of OPB-111077, as determined by the EORTC PET response criteria. | 3 years | |
Secondary | Progression free survival | This is defined as the time from the start of study treatment to documented progression of disease or death. | 3 years | |
Secondary | Haematologic and non-haematologic toxicities (all grades) | To evaluate the haematologic and non-haematologic toxicities of OPB-111077 | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05099549 -
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT06202599 -
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
|
||
Recruiting |
NCT04900519 -
Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04239092 -
9-ING-41 in Pediatric Patients With Refractory Malignancies.
|
Phase 1 | |
Withdrawn |
NCT04809012 -
Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06047860 -
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05767684 -
Neoantigen Derived DCs as Cancer Treatment
|
Phase 1 | |
Not yet recruiting |
NCT06456138 -
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT03239015 -
Efficacy and Safety of Precision Therapy in Refractory Tumor
|
Phase 2 | |
Completed |
NCT03415477 -
Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts
|
Phase 1/Phase 2 | |
Recruiting |
NCT05752552 -
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
|
Phase 1 | |
Completed |
NCT02564198 -
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06098651 -
A Study of DCR-STAT3 in Adults With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05790447 -
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
|
Phase 2 |